Assessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry Manaswini Pillai, Simon Erridge, Lara Bapir, Martha Nicholas, Nishaanth Dalavaye, Carl Holvey, Ross Coomber, Daniela Barros, Urmila Bhoskar, Gracia Mwimba, Kavita Praveen, Chris Symeon, Simmi Sachdeva-Mohan, James J Rucker and Mikael H Sodergren Expert Review of Neurotherapeutics, 2022, 22, 11–12, 1009–1018. Doi : 10.1080/14737175.2022.2155139 ABSTRACT Background : The current paucity of clinical evidence limits the use of cannabis-based medicinal products (CBMPs) in post-traumatic stress disorder (PTSD). This study investigates health-related quality of life (HRQoL) changes and adverse events in patients prescribed CBMPs for PTSD. Methods : A case-series of patients [...]
Lire la suiteCannabis containing equivalent concentrations of delta‐9‐tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC‐dominant cannabis Nadia R. P. W. Hutten, T. R. Arkell, F. Vinckenbosch, J. Schepers, R. C. Kevin, E. L. Theunissen, K. P. C. Kuypers, I. S. McGregor, J. G. Ramaekers Psychopharmacology, 2022, 239, 3731–3741 Doi : 10.1007/s00213-022-06248-9 Abstract Rationale : Delta-9-tetrahydrocannabinol (THC), an active component of cannabis, can cause anxiety in some users during intoxication. Cannabidiol (CBD), another constituent of cannabis, has anxiolytic properties suggesting that cannabis products containing CBD in addition to THC may produce less anxiety than THC-only products. Findings to date around this issue have been inconclusive and [...]
Lire la suiteCannabidiol as an add-on therapy to overcome the slow-onset and, possibly, resistance to antidepressant treatment : involvement of NAPE-PLD in the medial prefrontal cortex. Franciele F. Scarante, Vinícius D. Lopes, Eduardo J. Fusse, Maria A. Vicente, Melissa R. Araújo, Davi S. Scomparin, Rafael P. Aguiar, Francisco S. Guimarães, Viviani Nardinid, Carlos Arterio Sorgid, Lucia H. Faccioli, RhD, PhDd, Jaime E. C. Hallak, MD, PhDe,f; Samia Joca, Kenneth Mackie, Antonio Waldo Zuardi, José Alexandre S. Crippa, Alline C. Campos. bioRxiv preprint, April 26, 2021. doi : 10.1101/2021.04.23.441143 Highlights ● In mice, cannabidiol (CBD), but not escitalopram, induced a fast-onset anti-stress action. ● Combinations of sub-effective doses [...]
Lire la suiteThe Effects of Cannabinoids on Sleep Bhanu Prakash Kolla, Lisa Hayes, Chaun Cox, Lindy Eatwell, Mark Deyo-Svendsen , and Meghna P. Mansukhani Journal of Primary Care & Community Health, 2022, Volume 13, 1–9. Doi : 10.1177/21501319221081277 Abstract The use of cannabis products to help with sleep and various other medical conditions by the public has increased significantly in recent years. Withdrawal from cannabinoids can lead to sleep disturbance. Here, we describe a patient who developed significant insomnia leading to worsening anxiety, mood, and suicidal ideation in the setting of medical cannabis withdrawal, prompting presentation to the Emergency Department and inpatient admission. There is a limited [...]
Lire la suiteCannabidiol (CBD) in the Self-Treatment of Depression-Exploratory Study and a New Phenomenon of Concern for Psychiatrists Gniewko Wieckiewicz, Iga Stokłosa, Maciej Stokłosa, Piotr Gorczyca and Robert Pudlo Frontiers in Psychiatry, March 2022 | Volume 13 | Article 837946 doi : 10.3389/fpsyt.2022.837946 Cannabis sativa, whose flowers are also known as marijuana or marihuana, is a recreational plant that contains many chemicals that are constantly being studied by scientists around the world. One of these substances is cannabidiol (CBD), which has gained widespread popularity on the internet as a cure for mental health problems, leading many people to use CBD to self-treat depression and anxiety. This [...]
Lire la suiteBIBLIOGRAPHIE : Cannabinoïdes et maladies neurodégénératives Dr Christian Sueur, GRECC, mars 2022.
Lire la suiteEndocannabinoid System as Therapeutic Target of PTSD : A Systematic Review Luca Steardo, Jr., Elvira Anna Carbone, Giulia Menculini, Patrizia Moretti, Luca Steardo and Alfonso Tortorella Life, 2021, 11, 214. Doi : 10.3390/life11030214 Abstract : Post-Traumatic Stress Disorder (PTSD) is a complex disorder involving dysregulation of stress-related hormones and neurotransmitter systems. Research focused on the endocannabinoid system (eCBS) for anxiety and stress regulation, cognitive and emotional responses modulation and aversive memories extinction, leading to the hypothesis that it could represent a possible alternative treatment target for PTSD. In this systematic review, we summarize evidence about the efficacy and safety of medicinal cannabidiol (CBD), D9-tetrahydrocannabinol (D9-THC), and [...]
Lire la suiteExpérimentation clinico-pharmacologique de la prescription de CBD en clinique addictologique Projet CBD Thérapeutique, GRECC, version 3-5 Dr Christian SUEUR, mars 2022 112 pages Aujourd’hui, il n’est plus tabou au plan international de penser et d’appliquer des prescriptions de cannabinoïdes en clinique psychiatrique et addictologique.[1] En France, lors de la première séance du C.S.S.T. « Évaluation de la pertinence et de la faisabilité de la mise à disposition du cannabis en France », le 12 décembre 2018, c’est « le membre psychiatre » du C.S.S.T., le docteur George Brousse lui-même, qui souhaitait d’emblée « que soit mentionnée l’utilisation potentielle du CBD dans les troubles psychiatriques et de l’addiction, tout en précisant [...]
Lire la suiteThe Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances : Origins Samuel D. Banister and Mark Connor Handbook of Experimental Pharmacology, # Springer International Publishing AG, part of Springer Nature 2018 doi : 10.1007/164_2018_143 Contents 1 Introduction 2 Chemical Classification of Synthetic Cannabinoid Receptor Agonists 3 Cannabinoid Type 1 Receptor (CB1) Structure and Function 4 Historical Synthetic Cannabinoid Receptor Agonists 4.1 Classical Cannabinoids and Phytocannabinoid Analogs 4.2 Nonclassical Cannabinoids 4.3 Aminoalkylindoles (AAIs) 5 Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances 5.1 Molecular Hybridization 5.2 Bioisosteric Fluorination 6 Conclusions References Abstract Synthetic cannabinoid receptor agonists (SCRAs) have proliferated as new psychoactive substances (NPS) over the past decade. Relative to other classes of NPS, SCRAs [...]
Lire la suiteCannabidiol modulation of oxidative stress and signalling Sonia R. Pereira, Becky Hackett, David N. O’Driscoll, Melody Cui Sun and Eric J. Downer Neuronal Signaling, 2021, 5, NS20200080 doi : 10.1042/NS20200080 Cannabidiol (CBD), one of the primary non-euphoric components in the Cannabis sativa L. plant, has undergone clinical development over the last number of years as a therapeutic for patients with Lennox-Gastaut syndrome and Dravet syndromes. This phytocannabinoid demonstrates functional and pharmacological diversity, and research data indicate that CBD is a comparable antioxidant to common antioxidants. This review gathers the latest knowledge regarding the impact of CBD on oxidative signalling, with focus on the proclivity [...]
Lire la suite